• Access To Financings
  • Transparent
  • Innovative
  • Well-Connected

Full interview: ChemioCare begins dosing humans with its Olanzapine-based therapy

ChemioCare CEO Pedro Lichtinger tells Proactive the New York-based biotechnology company focused on transdermal delivery has begun dosing human patients with its lead therapy CMIO-OLANZ, an Olanzapine transdermal patch, to treat Poly (ADP-ribose) polymerase (PARP) inhibitor-induced nausea and vomiting.

Lichtinger says cancer patients treated with PARP inhibitors are projected to capture 60% of first-line therapy in ovarian cancer. In ChemioCare’s study, the company will measure blood levels of transdermal delivery and skin irritation, the gate-keeper to enter Phase 3 clinical programs.